Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE).

Autor: Saccardi R; Cellular Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy. riccardo.saccardi@aouc.unifi.it., Putter H; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Eikema DJ; EBMT Statistical Unit Leiden, Leiden, the Netherlands., Busto MP; EBMT Registry, Leiden, the Netherlands., McGrath E; ICCBBA, Barcelona, Spain., Middelkoop B; EBMT Registry, Leiden, the Netherlands., Adams G; EBMT Executive Office, Barcelona, Spain., Atlija M; EBMT Registry, Leiden, the Netherlands., Ayuk FA; Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany., Baldomero H; Centre for Hematology and Oncology, University Hospital Basel, Basel, Switzerland., Beguin Y; Department of Hematology, CHU of Liège and University of Liège, Liège, Belgium., de la Cámara R; Infectious Diseases Working Party (IDWP), Barcelona, Spain., Cedillo Á; Grupo Español de Trasplantes Hematopoyéticos y Terapia Celular (GETH-TC), Madrid, Spain., Balari AMS; Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Chabannon C; Centre de Thérapie Cellulaire, Institut Paoli-Calmettes Comprehensive Cancer Centre, Aix-Marseille Université School of Medicine & Inserm CBT-1409, Centre d'Investigations Cliniques en Biothérapies, Marseille, France., Corbacioglu S; Department of Paediatric Oncology, Haematology and Stem Cell Transplantation, University Children's Hospital Regensburg, Regensburg, Germany., Dolstra H; Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands., Duarte RF; Hospital Universitario Puerta de Hierro Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain., Dulery R; Sorbonne Université, INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France., Greco R; Blood and Marrow Transplant (BMT) Unit, IRCCS San Raffaele Hospital, Milan, Italy.; Autoimmune Diseases Working Party (ADWP), EBMT, Barcelona, Spain., Gusi A; EBMT Executive Office, Barcelona, Spain., Hamad N; Department of Haematology, St Vincent's Hospital Sydney, Sydney, NSW, Australia.; School of Clinical Medicine, UNSW Medicine & Health, Kensington, NSW, Australia.; School of Medicine, Sydney, University of Notre Dame Australia, Sydney, WA, Australia., Kenyon M; Kenyon, M, Department of Haematology, King's College Hospital NHS Foundation Trust, London, United Kingdom., Kröger N; Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany., Labopin M; Sorbonne University, Department of Hematology, Hôpital Saint Antoine, and INSERM UMRs 938, Paris, France.; EBMT Paris Study Office, Paris, France., Lee J; British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) Data Registry, London, United Kingdom., Ljungman P; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Manson L; Edinburgh & SE Scotland Clinical Transfusion Centre Patient Services and the Edinburgh & SE Scotland Clinical Apheresis Unit, Edinburgh, United Kingdom., Mensil F; Agence de la Biomédecine, Saint-Denis, France., Milpied N; Centre Hospitalier Universitaire (CHU) Bordeaux, Service d'Hematologie et Therapie Cellulaire, Bordeaux, France., Mohty M; Sorbonne University, Hôpital Saint Antoine (AP-HP), and INSERM UMRs 938, Paris, France., Oldani E; Italian National BMT Registry (GITMO), Bergamo, Italy., Orchard K; University Hospital Southampton NHS, London, United Kingdom., Passweg J; Hematology division, Basel University Hospital, Basel, Switzerland., Pearce R; British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) Data Registry, London, United Kingdom., de Latour RP; BMT unit Paris Cité University, French reference center for aplastic anaemia and PNH, French rare network for rare immunological and haematological disorders (MaRIH), Severe aplastic anaemia working party of the European blood and marrow transplantation group (SAAWP EBMT) Saint-Louis Hospital, Paris, France., Poirel HA; Belgian Transplant Registry, Belgian Cancer Registry, Brussels, Belgium., Rintala T; King's College Hospital NHS Foundation Trust, London, United Kingdom., Rizzo JD; CIBMTR, Medical College of Wisconsin, Milwaukee, WI, USA., Ruggeri A; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy., Sanchez-Martinez C; JACIE, EBMT Executive Office, Barcelona, Spain., Sanchez-Guijo F; CIC-University of Salamanca, IBSAL-University Hospital of Salamanca, Salamanca, Spain., Sánchez-Ortega I; EBMT Executive Office, Barcelona, Spain., Trnková M; Czech registry, Prague, Czech Republic., Ferreiras DV; Grupo Español de Trasplantes Hematopoyéticos y Terapia Celular (GETH-TC), Madrid, Spain.; Hematology Department, Vall d'hebron Institut Oncologic (VHIO), Hospital Vall d'hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Wilcox L; Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Darlinghurst, NSW, Australia., de Wreede LC; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2023 Jun; Vol. 58 (6), pp. 659-666. Date of Electronic Publication: 2023 Mar 09.
DOI: 10.1038/s41409-023-01924-6
Abstrakt: From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT process and meeting FACT-JACIE accreditation requirements relating to 1-year survival outcomes. Informed by previous experience from Europe, North America and Australasia, the Clinical Outcomes Group (COG) established criteria for patient and Center selection, and a set of key clinical variables within a dedicated statistical model adapted to the capabilities of the EBMT Registry. The first phase of the project was launched in 2019 to test the acceptability of the benchmarking model through assessment of Centers' performance for 1-year data completeness and survival outcomes of autologous and allogeneic HSCT covering 2013-2016. A second phase was delivered in July 2021 covering 2015-2019 and including survival outcomes. Reports of individual Center performance were shared directly with local principal investigators and their responses were assimilated. The experience thus far has supported the feasibility, acceptability and reliability of the system as well as identifying its limitations. We provide a summary of experience and learning so far in this 'work in progress', as well as highlighting future challenges of delivering a modern, robust, data-complete, risk-adapted benchmarking program across new EBMT Registry systems.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: